A phase II study of erlotinib for gefitinib-resistant non-small cell lung cancer without T790M mutation analyzed in the circulating tumor cell
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000004046
- Lead Sponsor
- orth-East Japan Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Clinical symptomatic brain metastasis 2. With severe co-morbidities
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate
- Secondary Outcome Measures
Name Time Method